Enanta Pharmaceuticals, Inc. — FY2015 Form 10-K Summary
Reporting period: Fiscal year ended September 30, 2015; the filing also reports the quarter ended September 30, 2015. Filed December 11, 2015. Amounts are in U.S. dollars unless noted.
Business context
Enanta is a research-and-development-focused biotechnology company developing small-molecule treatments for viral infections and liver diseases. Its principal commercial exposure is through AbbVie’s marketing of paritaprevir-containing hepatitis C (HCV) regimens, for which Enanta receives milestone payments and royalties. Enanta’s wholly owned programs include the HCV cyclophilin inhibitor EDP-494 and FXR agonists for NASH and potentially PBC; neither program had generated product sales.
Financial results and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Revenue | $160.9 million | $47.7 million |
| Operating expenses | $36.7 million | $28.8 million |
| Operating income | $124.1 million | $19.0 million |
| Net income | $79.0 million | $34.4 million |
| Diluted EPS | $4.09 | $1.80 |
| Operating cash flow | $76.7 million | $20.2 million |
| Cash, cash equivalents and marketable securities, year-end | $209.4 million | $131.8 million |
| Working capital, year-end | $163.9 million | $103.2 million |
- Revenue increased approximately 237% year over year, primarily from $125.0 million of AbbVie milestones and $34.1 million of royalties. Revenue was concentrated in collaboration income, rather than sales of Enanta’s own products.
- Operating margin was approximately 77% and net margin approximately 49% in FY2015; these margins reflect milestone and royalty revenue and should not be viewed as a steady-state product-sales profile.
- R&D expense rose to $23.2 million from $18.7 million; G&A expense rose to $13.5 million from $10.0 million. Management expected R&D spending to increase as internal programs advance.
- FY2015 operating cash flow included timing effects from receivables; accounts receivable increased, including royalties due from AbbVie. Investing activities used $88.2 million, largely reflecting purchases of marketable securities.
- Enanta reported no debt outstanding. Total liabilities were $9.9 million, including $1.4 million of warrant and preferred-stock fair-value liabilities. The company stated existing resources should fund operations for the foreseeable future, while noting this depends on uncertain development costs and AbbVie revenue.
- FY2015 tax expense was $46.5 million, versus a $15.2 million tax benefit in FY2014, when Enanta released its deferred-tax valuation allowance.
Quarterly and year-over-year developments
- FY2015 fourth-quarter revenue was $14.4 million, compared with $2.6 million in the prior-year quarter; net income was $5.8 million versus a $5.0 million net loss. Quarterly results were uneven, with most FY2015 revenue recognized in the first two quarters.
- AbbVie’s paritaprevir regimens generated $469 million in reported gross sales for the quarter ended September 30, 2015, resulting in $14.3 million of royalties to Enanta for that quarter.
- Enanta received $125 million in FY2015 milestone payments, compared with $40 million in FY2014. It earned a further $30 million milestone in November 2015 upon Japanese reimbursement approval for VIEKIRAX; this is post-year-end and was not FY2015 revenue.
- AbbVie reported Phase 2 results for ABT-493/ABT-530 in November 2015 and initiated the first Phase 3 study. AbbVie targeted a first U.S. approval in 2017; timing and success remain uncertain.
- Enanta ended its NIAID-funded antibiotic program in August 2015 and is no longer conducting antibiotic research. R&D spending shifted toward NASH and cyclophilin programs.
Outlook, risks and contingencies
- Management planned to begin EDP-494 HCV clinical trials in the first quarter of calendar 2016 and to initiate an FXR-agonist clinical program in calendar 2016. These are plans, not assurances of trial initiation or success.
- Near-term revenue and profitability remain dependent on AbbVie’s development, commercialization, market access and sales of paritaprevir-containing regimens, and potential future ABT-493 milestones and royalties. AbbVie controls those development and commercialization decisions and may terminate the collaboration on specified notice.
- Management cited intense HCV competition, changing treatment standards and payer reimbursement, potential market-share erosion, and the possibility that competing therapies reduce royalty revenue. Royalties are subject to contractual sales allocations and potential reductions.
- The filing discusses an October 2015 FDA warning letter concerning risks of VIEKIRA PAK and TECHNIVIE in patients with decompensated cirrhosis. The company said the commercial impact was not yet clear.
- Clinical, regulatory, safety, manufacturing, intellectual-property and collaboration risks could delay or prevent development. Enanta relies on third parties for manufacturing and clinical work and has no independent commercial sales infrastructure.
- The completed NIAID contract is subject to government audit and possible adjustment of reported revenue or reimbursement. The company reported no material legal proceedings. Contractual lease commitments totaled $15.2 million; a potential $2.0 million preferred-stock liquidation payment depends on warrant exercise and a qualifying transaction.
Most important facts for investors to verify
- Whether AbbVie’s paritaprevir sales, market share, payer access and reported royalties support the assumed revenue outlook, including the effect of the FDA warning and competing HCV regimens.
- Whether the November 2015 $30 million Japan milestone is recognized in FY2016 and how the remaining potential ABT-493 milestones and royalty allocation terms work.
- Whether EDP-494 and the FXR program enter clinical trials on the stated timelines, and the resulting R&D spending and safety or efficacy findings.
- Cash and investment balances, receivable collections, and whether the stated funding runway remains adequate as internal-program expenses rise.
- Any outcome of the NIAID contract audit, changes in lease or other commitments, and developments affecting the AbbVie collaboration or Enanta’s intellectual-property position.